SAN DIEGO, Nov. 7, 2016 /PRNewswire/ -- NI Research has released the November/December issue of NeuroPerspective, which features comprehensive reviews of two major therapeutic areas, Multiple Sclerosis and Pain (non-neuropathic). Photo - http://photos.prnewswire.com/prnh/20161104/436454LOGO As NeuroPerspective publisher Harry Tracy PhD notes: "The areas of MS and Pain share some attributes: While the industry has enjoyed great commercial success, and there are treatments in each area that offer therapeutic benefit, there is a price to be paid for these successes. In MS, there is a perennial tradeoff between the magnitude of impact and the risk of a compromised immune system unable to fend off infections and/or cancer, while the treatment of pain has fostered an epidemic of prescription opioid and heroin addiction. There is a high need for improvement in the options available for both therapeutic areas." Multiple Sclerosis represents the area where neuroscience has achieved the greatest progress towards slowing the course of a CNS disease, and where patients and their physicians can choose from a variety of treatment approaches (i.e. the ABC drugs, Tysabri, the oral immunomodulators) for the treatment of RRMS. Yet all of these drugs have their own flaws and risks, and there have been no real options for Progressive MS. Both Roche and Novartis have now reported positive Phase III results in Progressive MS, for ocrelizumab and sipinimod respectively. MS is also the area where regenerative therapies are likely to emerge as an avenue to repairing the damage done, and while the first trial of Biogen's anti-lingo program failed, there are glimmers of hope from retrospective dosing analysis that this may yet be fruitful. This review covers programs from Biogen, Roche, Novartis, Teva, Sanofi, Acorda, MedDay, Merck Serono, Actelion and many more.